ClinicalTrials.gg
RecruitingNCT06544135TICUpdated Jul 2, 2026

Use of Thermal Imaging Camera to Assess Perfusion Before and After Vascular Intervention

An observational study in Peripheral Arterial Disease, Critical Limb Ischemia and Critical Lower Limb Ischemia, sponsored by University Hospitals Cleveland Medical Center. Recruiting at 3 sites in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-07-02.

Primary conditionChronic Limb-Threatening IschemiaRegistry: Peripheral Arterial DiseaseReclassifiedWhy we changed it
Registry
Peripheral Arterial Disease — the first condition term the registry derived for this study.
ClinicalTrials.gg
Chronic Limb-Threatening Ischemia
Why
  1. The study's listed conditions name Chronic Limb-Threatening Ischemia, a narrower term within Peripheral Arterial Disease.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University Hospitals Cleveland Medical Center · Observational

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
25
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 105 studies in Chronic Limb-Threatening Ischemia with a site in United States — 13 open to participants now, 20 under way, 2 of them phase 3. Chronic Limb-Threatening Ischemia · United States.

Planned enrollment
17th of 19
25 · median 102
Started
2025
with 3 others
Observational
19 of 105
3 open now
Primary completion
2027-10
later than 15 of 19 live
Registered
102nd of 105
by date
Lead sponsor
3 of 105
University Hospitals Cleveland Medical Center

Among the 105 studies in Chronic Limb-Threatening Ischemia with a site in United States, this one is the 17th largest by planned enrollment of the 19 observational ones that give a count, is one of 4 that started in 2025, is one of 19 observational ones, reaches primary completion later than 15 of the 19 other live ones, and was the 102nd registered.

Chronic Limb-Threatening Ischemia

359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.

Browse Chronic Limb-Threatening Ischemia studies →

Open to participants now

13 of the 105 studies in Chronic Limb-Threatening Ischemia with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 51 Chronic Limb-Threatening Ischemia studies recruiting now, 35 (69%) set no upper age limit and 2 (4%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 105 studies in Chronic Limb-Threatening Ischemia with a site in United States, or all of them as a file.
02

Study summary

This is a preliminary prospective observational study measuring change in lower extremity temperature in response to revascularization procedure.

The main question this study aims to answer is:

- Are temperature measurements from a forward looking infrared (FLIR) camera of the lower extremity useful in predicting outcome of revascularization procedures?

Read the detailed description

This is a preliminary prospective observational study measuring change in lower extremity temperature in response to revascularization procedure.

Patients with lower extremity PAD will be seen in office pre-intervention. Consent to participate in the TIC study will be acquired at this point. Patients will be given a physical copy of their consent form at the time consent is obtained. During this initial visit or subsequent pre-procedural office visit, the smartphone-based thermal camera will be utilized to measure the temperature of the lower extremity foot, ankle, and leg at the plantar, dorsal, and lateral distributions. Comorbidities and demographic factors will be documented from medical records at this time as well.

Data will be gathered at a consistent location to minimize impact of room temperature on measurements.

Patients will then undergo scheduled revascularization with the interventionist.

Post-intervention pictures will be taken immediately after revascularization.

Patients will then be seen again by the research team for follow-up thermal camera imaging, 1 week post-intervention, and weekly post intervention for at least 1 month but up to 6 months.

Thermal measurements will be correlated with intra-op imaging and clinical outcomes in data analysis.

03

Conditions studied

  • Peripheral Arterial Disease
  • Critical Limb Ischemia
  • Critical Lower Limb Ischemia

Browse trials for

04

In context

Chronic Limb-Threatening Ischemia Reclassified

359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.

This study's planned enrollment of 25 is below the median of 111 across 104 observational studies indexed under Chronic Limb-Threatening Ischemia.

Browse Chronic Limb-Threatening Ischemia studies →

Lead sponsor

University Hospitals Cleveland Medical Center is the lead sponsor of 296 studies on the registry; 46 are open to participants now.

Of its 36 completed or terminated interventional studies of FDA-regulated products, 30 (83%) have results posted.

Compared within Chronic Limb-Threatening Ischemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Peripheral Arterial Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

People between ages 18 and 99 years with lower extremity peripheral artery disease with a planned endovascular intervention.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Lower extremity peripheral artery disease with tissue loss consistent with Rutherford classification V or VI.
  • Planned lower extremity endovascular intervention

Exclusion criteria

Exclusion Criteria:

  • Non-arterial ulcers
  • Pregnant
06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
25 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • FLIR thermal imaging group

    Temperature measurements will be taken of the lower limb using the FLIR camera and correlated with other aspects of each patient.

    Device: FLIR One Pro LT

Interventions

  • DeviceFLIR One Pro LT

    Thermal imaging camera used to measure temperatures of the lower limb.

07

What researchers measure

Primary outcomes

  1. Change in ABI

    Ankle brachial index will be taken before and after intervention and correlated with thermal readings from FLIR.

    Time frame: Up to 90 days before revascularization; Up to 1 year after revascularization

Secondary outcomes

  1. Major amputations

    Any associated amputations the subject had after revascularization

    Time frame: Up to 1 year after revascularization

  2. Major revascularizations post-initial intervention

    Any revascularization procedures done after the initial revascularization

    Time frame: Up to 1 year after revascularization

  3. Mortality

    Subject deaths during the length of the study

    Time frame: Up to 1 year after revascularization

08

Study locations

3 of 3 sites recruiting
  • University Hospitals Ahuja Medical Center
    Beachwood, Ohio 44122, United States
    Recruiting
    • Jun Li, MD · Contact
    • Tarek Hammad, MD · Sub investigator
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
    Recruiting
    • Jun Li, MD · ContactJun.Li@UHhospitals.org · 440-882-0075
    • Mehdi H Shishehbor, DO · Sub investigator
    • Tarek Hammad, MD · Sub investigator
  • University Hospitals Parma Medical Center
    Parma, Ohio 44129, United States
    Recruiting
    • Jun Li, MD · Contact
    • Yulanka Castro, MD · Sub investigator
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Oct 2027, 30 months after the start.

Of 47 non-industry observational studies under Chronic Limb-Threatening Ischemia, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 60. This study's planned 30 months is below that.

Counting every sponsor, half of 53 studies reached it within 34 months; a quarter within 22 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2024
First posted
Aug 9, 2024
StartActual
Apr 14, 2025
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2027
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06544135
Responsible party
Sponsor
First posted
Aug 9, 2024
Start date
Apr 14, 2025
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Jul 2, 2026

Study contacts

Jun Li, MD
Contact
jun.li@uhhospitals.org
(734) 968-5212
Grace Craig, DPM
Contact
gracecraigdpm@gmail.com
408 628 8102
Jun Li, MD
principal investigator · University Hospitals

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion